Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Phase I Study Of Paclitaxel And Epirubicin, Without And With Filgrastim, For The Treatment Of Platinum-Resistant Advanced Ovarian Cancer

R. Lauria, E. Ferrari, S. Tramontana, A. Morabito, F. Perrone, A. Maffeo, R. Fiorentino, G. Casella, F. Iodice, P. Ricchi, C. Carlomagno, E. Varriale, G. de Placido, S. de Placido, A. Bianco, S. Pignata
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The aim of the study was to determine the maximum tolerated dose (MTD) of epirubicin combined with a fixed dose of paclitaxel, without and with support of filgrastim, in patients with platinum resistant or refractory ovarian cancer. Paclitaxel (150 mg/m2) and epirubicin (starting dose 90 mg/m2, 15 mg/m2 escalation per level) were given on day 1, every 28 days for 4–6 cycles. Filgrastim (F) (5 µg/kg/die) was given in case of grade 4 leukopenia (levels without support) or from day 4 up to leukocyte count >10,000/mm3 after nadir (levels with support). Cohorts of 3 patients were enrolled at each level and further 3 patients were planned if 1 or 2 unacceptable toxic events (UTE) were registered. MTD was determined first without and then with filgrastim. Four levels were studied (90, 90+F, 105+F, 120+F) with 4, 6, 5 and 4 patients enrolled, respectively. UTE (grade 4 neutropenia) were observed in 3 patients at level 1. Thus, 90 mg/m2 was the MTD for epirubicin without filgrastim. MTD of epirubicin with filgrastim was not reached at 120 mg/m2. Hematological toxicity was mild. Grade 3 mucositis was reported in 1 patient. Among the 14 patients with measurable or evaluable disease, 3 objective responses were observed (1 complete and 2 partial) for an overall response rate of 21.4%. The combination of paclitaxel 150 mg/m2 and epirubicin at 120 mg/m2 with filgrastim is a feasible therapy. Grade 4 leukopenia is the dose limiting toxicity using epirubicin at 90 mg/m2 without filgrastim.
This paper references
Chemotherapy in ovarianc carcinoma : Present role and future prospects
JT Thigpen (1989)
High-dose intensity regimens with epirubicin in ovarian cancer.
J. Vermorken (1994)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
W. Mcguire (1989)
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
J. Thigpen (1994)
Buzdar AU: Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer
GN Hortobagyi (1997)
Randomized trials of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma : A Gynecologic Oncology Group Study
K Bertelsen (1989)
A phase II study of epirubicin in advanced ovarian carcinoma; in Bonadonna G (ed): Advances in Anthracycline Chemotherapy: Epirubicin
C Tropé (1984)
Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.
R. Ozols (1980)
A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
D. Amadori (1996)
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.
J. Vermorken (1995)
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
E. Trimble (1993)
Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
P. Dombernowsky (1996)
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
F. Holmes (1996)
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer.
S. Pignata (1997)
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
K. Bertelsen (1987)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Randomized comparison of cisplatin with cyclophosphamide / cisplatin and with cyclophosphamide / doxorubicin / cisplatin in advanced ovarian cancer
GA Omura (1987)
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
G. Hortobagyi (1997)
Ovarian cancer: where to next?
R. Ozols (1991)
Phase I clinical and pharmacokinetic study of taxol.
P. Wiernik (1987)
Chemotherapy of ovarian cancer.
R. Ozols (1991)
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
G. Omura (1989)
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
P. Conte (1997)
Advanced epithelial ovarian cancer: 1993 consensus statements.
D. G. Allen (1993)
Cyclo - phosphamide plus cisplatin versus clophos - phamide , doxorubicin and cisplatin chemotherapy of ovarian carcinoma : A meta - analysis
C Tropé (1991)
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
E. Eisenhauer (1994)
Reporting results of cancer treatment
A. Miller (1981)
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
W. Wilson (1994)
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
J. Neijt (1991)
Chemotherapy in ovarian carcinoma: present role and future prospects.
J. Thigpen (1989)
Taxol: a novel investigational antimicrotubule agent.
E. Rowinsky (1990)
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
G. Catimel (1996)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar